Our Team
Prof. Dr. Carsten Werner
Prof. Dr. Caghan Kizil
Our team is a unique combination of scientists and business executives culminating innovative ideas and perfect scientific execution with sustainable financial stability and R&D capacity. We place great importance on R&D to dynamically match the needs of our customers.
Prof. Dr. Caghan Kizil
Prof. Dr. Carsten Werner
Prof. Dr. Caghan Kizil
Co-founder, Chief Executive Officer
Caghan Kizil is a W2 tenured professor of neuroscience at German Center for Neurodegenerative Diseases (DZNE) within Helmholtz Association in Dresden, Germany and Visiting Professor at Columbia University Irving Medical Center, New York, USA. His research focuses on understanding the molecular mechanism
Co-founder, Chief Executive Officer
Caghan Kizil is a W2 tenured professor of neuroscience at German Center for Neurodegenerative Diseases (DZNE) within Helmholtz Association in Dresden, Germany and Visiting Professor at Columbia University Irving Medical Center, New York, USA. His research focuses on understanding the molecular mechanisms of regeneration in nervous system after neurodegeneration by using animal models and in vitro 3D human brain cultures. He received several awards including Helmholtz Young Investigator Award, Helmholtz Validation Funds of the President's Initiative, DZNE Innovation-to-Application Award, and Columbia University Schaefer Research Scholars Award.
Prof. Dr. Carsten Werner
Prof. Dr. Carsten Werner
Prof. Dr. Carsten Werner
Co-founder, Scientific Advisor
Carsten Werner is a professor for Biofunctional Polymer Materials at the Technische Universität Dresden, Center for Regenerative Therapies Dresden and directs the Biomaterials program at the Leibniz Institute of Polymer Research Dresden/Max Bergmann Center of Biomaterials Dresden (Germany). His research aims
Co-founder, Scientific Advisor
Carsten Werner is a professor for Biofunctional Polymer Materials at the Technische Universität Dresden, Center for Regenerative Therapies Dresden and directs the Biomaterials program at the Leibniz Institute of Polymer Research Dresden/Max Bergmann Center of Biomaterials Dresden (Germany). His research aims at recapitulating functionalities of living matter in engineered polymer materials and includes studies on electrosurface phenomena, hemocompatibility of biomaterials and cell-instructive materials platforms for regenerative therapies and tissue models.
Dr. Uwe Freudenberg
Dr. Stanislava Popova
Prof. Dr. Carsten Werner
Co-founder
Uwe Freudenberg is a group leader for Matrix Engineering at the Institute of Biofunctional Polymer Materials at the Leibniz Institute of Polymer Research Dresden, Germany (IPF). He received his doctoral degree (Dr.-Ing.) from the Faculty of Mechanical Science and Engineering at the Technische Universität Dresden in 2007. His cur
Co-founder
Uwe Freudenberg is a group leader for Matrix Engineering at the Institute of Biofunctional Polymer Materials at the Leibniz Institute of Polymer Research Dresden, Germany (IPF). He received his doctoral degree (Dr.-Ing.) from the Faculty of Mechanical Science and Engineering at the Technische Universität Dresden in 2007. His current research focuses on the development of multifunctional polymer materials for biomedical applications with special emphasis on GAG-based hydrogels.
...
Dr. Stanislava Popova
Dr. Stanislava Popova
Dr. Stanislava Popova
Senior R&D Associate
Stanislava Popova received her PhD degree from the Faculty of Medicine "Carl Gustav Carus" at the Technische Universität Dresden and performed her postdoctoral research in German Center for Neurodegenerative Diseases (DZNE). Her expertise includes gene silencing, genomic engineering, recombinant technologies, 3D hydr
Senior R&D Associate
Stanislava Popova received her PhD degree from the Faculty of Medicine "Carl Gustav Carus" at the Technische Universität Dresden and performed her postdoctoral research in German Center for Neurodegenerative Diseases (DZNE). Her expertise includes gene silencing, genomic engineering, recombinant technologies, 3D hydrogel cultures, cell-based metabolic assays, animal models of disease, and high-throughput assay automation and optimization.
...
Dr. Rajvinder Kaur
Dr. Stanislava Popova
Dr. Stanislava Popova
R&D Associate
Rajvinder Kaur is a neurobiologist, received her Ph.D. degree from the Faculty of Biology at the Technische Universität Darmstadt, Germany. Her cross-disciplinary research expertise includes pharmacological modulators and ionizing radiation, neuronal activity and plasticity, 2D and 3D mammalian cell culture systems, stem cell
R&D Associate
Rajvinder Kaur is a neurobiologist, received her Ph.D. degree from the Faculty of Biology at the Technische Universität Darmstadt, Germany. Her cross-disciplinary research expertise includes pharmacological modulators and ionizing radiation, neuronal activity and plasticity, 2D and 3D mammalian cell culture systems, stem cell differentiation, cell-based biochemical assays, array-based extracellular recordings, animal research, and imaging.
.jpg/:/cr=t:16.12%25,l:10.53%25,w:70.42%25,h:46.93%25/rs=w:365,h:365,cg:true,m)
Tina Ramberg
Tina Ramberg
Tina Ramberg
R&D Associate
Tina Ramberg holds an MSc degree in biotechnology and worked at the Leibniz Institute of Polymer Research Dresden (IPF) during her studies. There she gained extensive knowledge of 3D hydrogel systems, cell culture, high throughput automation and optimization.
Klara Czobor
Tina Ramberg
Tina Ramberg
Market Strategy Consultant
Klara Czobor is an accomplished medical communications specialist, pharmaceutical analyst, and medical/scientific reporter. She has been responsible for the development of a number of high-profile disease-state and branded promotional materials targeting a variety of key clinical and pharmaceutical audiences. Kla
Market Strategy Consultant
Klara Czobor is an accomplished medical communications specialist, pharmaceutical analyst, and medical/scientific reporter. She has been responsible for the development of a number of high-profile disease-state and branded promotional materials targeting a variety of key clinical and pharmaceutical audiences. Klara's responsibilities as a pharmaceutical analyst and reporter have included conducting interviews with KOLs, regulatory officials, and executives, and attending conferences to provide real-time clinical/regulatory medical information to pharmaceutical companies and investors. She has a comprehensive knowledge of the clinical profiles and marketing strategies that support multiple diverse pharmaceutical products. Klara is founder and CEO of Premier Endpoint and is the President of PharmaAcuity.
Ezgi Eris
Tina Ramberg
Dr. Nambirajan Govindarajan
Market Strategy Consultant
Ezgi Eris has over 10 years of pharmaceutical experience in medical strategy development, KOL relationship management, medical projects, clinical research, and drug safety. She was a hematology/ oncology MSL at Celgene for 9 years. She later served within the business strategy department of a healthcare agency th
Market Strategy Consultant
Ezgi Eris has over 10 years of pharmaceutical experience in medical strategy development, KOL relationship management, medical projects, clinical research, and drug safety. She was a hematology/ oncology MSL at Celgene for 9 years. She later served within the business strategy department of a healthcare agency that focuses on developing promotional materials in the area of neurological diseases.
Dr. Nambirajan Govindarajan
Dr. Nambirajan Govindarajan
Dr. Nambirajan Govindarajan
Strategic Advisor
Dr. N. Govindarajan works as Research and Innovation Manager at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, bridging the fields of Artificial Intelligence and Life Sciences. Govind brings to our team his decade-long research experience in neurodegeneration along with many years of work experience in
Strategic Advisor
Dr. N. Govindarajan works as Research and Innovation Manager at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, bridging the fields of Artificial Intelligence and Life Sciences. Govind brings to our team his decade-long research experience in neurodegeneration along with many years of work experience in grants consultancy, R&D, and business strategies to ensure our lasting impact on the drug development technology landscape.